O	0	1	A
O	2	8	double
O	8	9	-
O	9	14	blind
O	14	15	,
O	16	27	multicenter
O	27	28	,
O	29	37	parallel
O	37	38	-
O	38	43	group
O	44	49	study
O	50	52	of
B-intervention	53	63	paroxetine
I-intervention	63	64	,
I-intervention	65	76	desipramine
O	76	77	,
O	78	80	or
B-control	81	88	placebo
O	89	91	in
O	92	98	breast
O	99	105	cancer
O	106	114	patients
O	115	116	(
O	116	122	stages
O	123	124	I
O	124	125	,
O	126	128	II
O	128	129	,
O	130	133	III
O	133	134	,
O	135	138	and
O	139	141	IV
O	141	142	)
O	143	147	with
O	148	153	major
O	154	164	depression
O	164	165	.

O	166	170	This
O	171	176	study
O	177	185	compared
O	186	189	the
O	190	198	efficacy
O	199	202	and
O	203	209	safety
O	210	212	of
O	213	223	paroxetine
O	224	227	and
O	228	239	desipramine
O	240	244	with
O	245	250	those
O	251	253	of
O	254	261	placebo
O	262	264	in
O	265	268	the
O	269	278	treatment
O	279	281	of
B-condition	282	292	depressive
I-condition	293	302	disorders
O	303	305	in
O	306	311	adult
O	312	317	women
O	318	322	with
O	323	329	breast
O	330	336	cancer
O	336	337	,
O	338	344	stages
O	345	346	I
O	346	347	-
O	347	349	IV
O	349	350	.

O	351	353	In
O	354	355	a
O	356	362	double
O	362	363	-
O	363	368	blind
O	368	369	,
O	370	377	placebo
O	377	378	-
O	378	388	controlled
O	389	394	study
O	394	395	,
B-total-participants	396	398	35
B-eligibility	399	405	female
I-eligibility	406	417	outpatients
I-eligibility	418	422	with
I-eligibility	423	429	breast
I-eligibility	430	436	cancer
I-eligibility	437	440	and
I-eligibility	441	444	DSM
I-eligibility	444	445	-
I-eligibility	445	448	III
I-eligibility	448	449	-
I-eligibility	449	450	R
I-eligibility	451	456	major
I-eligibility	457	467	depression
I-eligibility	468	470	or
I-eligibility	471	481	adjustment
I-eligibility	482	490	disorder
I-eligibility	491	495	with
I-eligibility	496	505	depressed
I-eligibility	506	510	mood
O	511	515	were
O	516	524	randomly
O	525	533	assigned
O	534	536	to
O	537	546	treatment
O	547	551	with
O	552	562	paroxetine
O	563	564	(
O	564	565	N
O	565	566	=
B-intervention-participants	566	568	13
O	568	569	)
O	569	570	,
O	571	582	desipramine
O	583	584	(
O	584	585	N
O	585	586	=
B-intervention-participants	586	588	11
O	588	589	)
O	589	590	,
O	591	593	or
O	594	601	placebo
O	602	603	(
O	603	604	N
O	604	605	=
B-control-participants	605	607	11
O	607	608	)
O	609	612	for
O	613	614	6
O	615	620	weeks
O	620	621	.

O	622	629	Primary
O	630	638	efficacy
O	639	642	was
O	643	651	assessed
O	652	654	by
B-outcome-Measure	655	661	change
I-outcome-Measure	662	666	from
I-outcome-Measure	667	675	baseline
I-outcome-Measure	676	678	in
I-outcome-Measure	679	684	score
I-outcome-Measure	685	687	on
I-outcome-Measure	688	691	the
I-outcome-Measure	692	694	21
I-outcome-Measure	694	695	-
I-outcome-Measure	695	699	item
I-outcome-Measure	700	708	Hamilton
I-outcome-Measure	709	715	Rating
I-outcome-Measure	716	721	Scale
I-outcome-Measure	722	725	for
I-outcome-Measure	726	736	Depression
I-outcome-Measure	737	738	(
I-outcome-Measure	738	741	HAM
I-outcome-Measure	741	742	-
I-outcome-Measure	742	743	D
I-outcome-Measure	743	744	)
O	744	745	,
O	746	749	and
O	750	753	the
O	754	763	secondary
O	764	771	outcome
O	772	779	measure
O	780	783	was
B-outcome-Measure	784	790	change
I-outcome-Measure	791	795	from
I-outcome-Measure	796	804	baseline
I-outcome-Measure	805	807	in
I-outcome-Measure	808	811	the
I-outcome-Measure	812	820	Clinical
I-outcome-Measure	821	827	Global
I-outcome-Measure	828	839	Impressions
I-outcome-Measure	839	840	-
I-outcome-Measure	840	848	Severity
I-outcome-Measure	849	851	of
I-outcome-Measure	852	859	Illness
I-outcome-Measure	860	865	scale
I-outcome-Measure	866	867	(
I-outcome-Measure	867	870	CGI
I-outcome-Measure	870	871	-
I-outcome-Measure	871	872	S
I-outcome-Measure	872	873	)
I-outcome-Measure	874	879	score
O	879	880	.

O	881	885	Mean
O	886	893	changes
O	894	896	in
O	897	900	the
O	901	906	total
O	907	910	HAM
O	910	911	-
O	911	912	D
O	913	916	and
O	917	920	CGI
O	920	921	-
O	921	922	S
O	923	929	scores
O	930	934	from
O	935	943	baseline
O	944	946	to
O	947	948	6
O	948	949	-
O	949	953	week
O	954	962	endpoint
O	963	966	for
O	967	970	the
O	971	981	paroxetine
O	982	985	and
O	986	997	desipramine
O	998	1004	groups
O	1005	1009	were
O	1010	1013	not
O	1014	1027	significantly
O	1028	1037	different
O	1038	1042	than
O	1043	1048	those
O	1049	1052	for
O	1053	1056	the
O	1057	1064	placebo
O	1064	1065	-
O	1065	1072	treated
O	1073	1078	group
O	1078	1079	.

O	1080	1082	An
O	1083	1092	unusually
O	1093	1097	high
B-outcome	1098	1102	rate
I-outcome	1103	1105	of
I-outcome	1106	1114	response
O	1115	1116	(
O	1116	1123	defined
O	1124	1126	as
O	1127	1128	>
O	1128	1130	or
O	1130	1131	=
O	1131	1133	50
O	1133	1134	%
O	1135	1146	improvement
O	1147	1149	in
O	1150	1153	the
O	1154	1157	HAM
O	1157	1158	-
O	1158	1159	D
O	1160	1165	score
O	1165	1166	)
O	1167	1169	in
O	1170	1173	the
O	1174	1181	placebo
O	1182	1187	group
O	1188	1191	was
O	1192	1200	observed
O	1201	1202	(
B-cv-bin-percent	1202	1204	55
I-cv-bin-percent	1204	1205	%
O	1206	1207	[
O	1207	1208	N
O	1208	1209	=
B-cv-bin-abs	1209	1210	6
O	1210	1211	]
O	1211	1212	)
O	1212	1213	;
O	1214	1221	adverse
O	1222	1228	events
O	1229	1241	precipitated
O	1242	1249	patient
B-outcome	1250	1265	discontinuation
O	1266	1268	in
O	1269	1272	the
O	1273	1279	active
O	1280	1289	treatment
O	1290	1296	groups
O	1297	1298	(
B-iv-bin-percent	1298	1299	9
I-iv-bin-percent	1299	1300	%
O	1301	1302	[
O	1302	1303	N
O	1303	1304	=
B-iv-bin-abs	1304	1305	1
O	1305	1306	]
O	1307	1310	for
O	1311	1322	desipramine
O	1322	1323	,
B-iv-bin-percent	1324	1326	15
I-iv-bin-percent	1326	1327	%
O	1328	1329	[
O	1329	1330	N
O	1330	1331	=
B-iv-bin-abs	1331	1332	2
O	1332	1333	]
O	1334	1337	for
O	1338	1348	paroxetine
O	1348	1349	)
O	1350	1357	similar
O	1358	1360	to
O	1361	1365	that
O	1366	1368	in
O	1369	1372	the
O	1373	1380	placebo
O	1380	1381	-
O	1381	1388	treated
O	1389	1397	patients
O	1398	1399	(
B-cv-bin-percent	1399	1401	18
I-cv-bin-percent	1401	1402	%
O	1403	1404	[
O	1404	1405	N
O	1405	1406	=
B-cv-bin-abs	1406	1407	2
O	1407	1408	]
O	1408	1409	)
O	1409	1410	.

O	1411	1422	Improvement
O	1423	1425	on
O	1426	1433	symptom
O	1434	1444	dimensions
O	1445	1451	within
O	1452	1455	the
O	1456	1459	HAM
O	1459	1460	-
O	1460	1461	D
O	1462	1465	and
O	1466	1474	Hamilton
O	1475	1481	Rating
O	1482	1487	Scale
O	1488	1491	for
O	1492	1499	Anxiety
O	1500	1501	(
B-outcome	1501	1511	depressive
I-outcome	1511	1512	,
I-outcome	1513	1520	anxiety
I-outcome	1520	1521	,
I-outcome	1522	1531	cognitive
I-outcome	1531	1532	,
I-outcome	1533	1548	neurovegetative
I-outcome	1548	1549	,
I-outcome	1550	1552	or
I-outcome	1553	1560	somatic
O	1560	1561	)
O	1562	1565	was
O	1566	1570	also
O	1571	1578	similar
O	1579	1586	between
O	1587	1593	groups
O	1593	1594	.

O	1595	1598	The
O	1599	1604	small
O	1605	1611	number
O	1612	1614	of
O	1615	1620	women
O	1621	1623	in
O	1624	1628	this
O	1629	1634	study
O	1635	1639	most
O	1640	1646	likely
O	1647	1658	contributed
O	1659	1661	to
O	1662	1665	the
O	1666	1670	lack
O	1671	1673	of
O	1674	1682	observed
O	1683	1694	differences
O	1695	1697	in
O	1698	1706	efficacy
O	1707	1715	observed
O	1716	1722	during
O	1723	1726	the
O	1727	1728	6
O	1729	1734	weeks
O	1735	1737	of
O	1738	1747	treatment
O	1747	1748	.

O	1749	1759	Randomized
O	1759	1760	,
O	1761	1768	placebo
O	1768	1769	-
O	1769	1779	controlled
O	1780	1786	trials
O	1787	1789	of
O	1790	1798	adequate
O	1799	1804	power
O	1805	1812	seeking
O	1813	1815	to
O	1816	1825	determine
O	1826	1834	efficacy
O	1835	1837	of
O	1838	1853	antidepressants
O	1854	1856	in
O	1857	1860	the
O	1861	1867	United
O	1868	1874	States
O	1875	1878	for
O	1879	1882	the
O	1883	1892	treatment
O	1893	1895	of
O	1896	1901	women
O	1902	1906	with
O	1907	1913	breast
O	1914	1920	cancer
O	1921	1924	and
O	1925	1933	comorbid
O	1934	1944	depression
O	1945	1951	remain
O	1952	1954	of
O	1955	1964	paramount
O	1965	1975	importance
O	1975	1976	.
